Infographic
The spatial edge in meningioma research
Posted on:
Meningiomas are the most common primary intracranial tumors1. High grade meningiomas have long posed a challenge in oncology due to limited treatment options. While surgical resection and radiotherapy have been the primary approaches, systemic therapies have proven ineffective, leaving patients and clinicians in need of innovative solutions. However, recent breakthroughs in spatial biology are shedding new light on meningiomas, providing critical insights that could lead to more targeted and successful treatments.
The spatial edge
Meningiomas manifest in a multitude of forms. From benign to aggressive tumors, their heterogeneity at cellular and molecular levels has been challenging to understand2. Spatial biology, at its core, emphasizes the importance of location and interaction. It deciphers the spatial distribution of cells, tissues, and their molecular constituents. By embedding the principles of spatial biology in meningioma research, researchers aim not only to observe cells but also to understand their spatial organization, potential interactions, and microenvironment influences.
Spatial biology’s contribution to meningioma research
Characterizing tumor heterogeneity
Varied pathogenic profiles of meningiomas, even within a single tumor, highlight a profound cellular heterogeneity. Spatial biology techniques, such as multiplex immunofluorescence (mIF), enable researchers to identify and characterize different cell populations within a tissue section. By preserving the architecture and localization of cells within their native microenvironment, mIF provides a multidimensional perspective of tissue organization and cellular interactions. Lucas et al. combined spatial transcriptomics, single-cell RNA-sequencing, and spatial proteomics3, including sequential immunofluorescence (seqIF™)4 on COMET™. The study used this multimodal approach to characterize the intratumor heterogeneity in low- versus high-grade meningioma and primary versus recurrent tumors using matched patient biopsies3 (Figure 1).
